Dicerna pushed up price and contacted other suitors before making deal with Novo Nordisk

Novo Nordisk wasn't alone in expressing interest in acquiring biotech business Dicerna, but after a bidding war, the Danish pharmaceutical company's offer was the most economically attractive, documents reveal.
Photo: Valdemar Ren
Photo: Valdemar Ren
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

When the hammer came down, Novo Nordisk's final bid for US-based Dicerna far exceeded its initial offer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading